Skip to content

Clinical efficacy of TCM syndrome differentiation in the treatment of severe/critical type of novel coronavirus pneumonia (COVID-19): a prospective, observational, one-arm clinical study

Clinical efficacy of TCM syndrome differentiation in the treatment of severe/critical type of novel coronavirus pneumonia (COVID-19): a prospective, observational, one-arm clinical study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2000003153
Enrollment
Unknown
Registered
2020-03-20
Start date
2020-03-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

Hospital of Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with severe and critical COVID-19 diagnosed in accordance with the Novel Coronavirus infected Pneumonia Diagnosis and Treatment Plan (Trial Version 6); 2. Aged >=18 years, both men and women; 3. Agree to participate in this test and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Those who cannot receive Chinese medicine treatment; 2. Patients with allergies to certain traditional Chinese medicine decoctions or traditional Chinese medicine injections; 3. Cases where complete diagnosis and treatment information cannot be obtained; 4. Any other chronic respiratory diseases, respiratory bacterial infections such as purulent tonsillitis, acute tracheobronchitis, sinusitis, otitis media, and other respiratory diseases affecting clinical trial evaluation; 5. Accompanied by basic diseases such as severe primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformation, congenital heart disease, and abnormal lung development; 6. Expected survival time is less than 1 week. Note: Anyone who meets any of the above exclusion criteria cannot be included in this test.

Design outcomes

Primary

MeasureTime frame
the ratio of patients transforming from severe/critical to light;fatality rate;Non-invasive/invasive mechanical ventilation time;

Secondary

MeasureTime frame
c reactive protein;Creatine Kinase Isoenzyme;Acute physiological and chronic health scores;Nucleic acid detection of novel coronavirus;troponin;arterial blood gas analysis;blood routine examination;ICU hospitalization days + total days in hospital;myohemoglobin;Modified sequential organ failure estimation score;D - dimer;erythrocyte sedimentation rate;procalcitonin;CT Scan-Chest;

Countries

China

Contacts

Public ContactPeiyang Gao

Hospital of Chengdu University of Traditional Chinese Medicine

gaopy930@126.com+86 18980025566

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026